More dates

Mind Medicine Australia SYDNEY: Introductory Workshop for Clinicians, Interested Professionals and Leaders on Psychedelic-Assisted Therapies with Dr Ben Sessa (UK)

This event has passed Get tickets

Event description

Tickets are strictly limited and early bird ticket offer ends on Friday October 27. Please register now before you miss out.

Don’t miss out - Get your tickets early!

Half day workshop presented by Mind Medicine Australia featuring Dr Ben Sessa (UK):

Introductory Workshop for Clinicians, Professionals and Leaders on Psychedelic-Assisted Therapies

A limited number of Medical and Allied Health Students may also register for these very special workshops.

Mind Medicine Australia is delighted to present a half day Introductory Workshop for Clinicians, Professionals and Leaders on Psychedelic-Assisted Therapies with Dr Ben Sessa (UK).

Dr Sessa has been at the forefront of psychedelic research for over 15 years through his affiliations with Bristol University and Imperial College London, under the auspices of Professor David Nutt. He brings a wealth of knowledge to this fast developing field in Australia.

In this workshop, Dr Sessa (UK) will explore how psychedelic-assisted therapy works by explaining:

  1. Neuropharmacology of MDMA and psilocybin and dosing protocols
  2. Preparing the therapist + facility/clinic
  3. What to expect / how to be ready
  4. Key features of the “set and setting”
  5. The “patient journey”
  6. Patient selection (inclusion and exclusion criteria, when to know that PAT might be the most appropriate next option)
  7. Obtaining consent (key concepts / risks to explain)
  8. Supportive care during drug tapering
  9. Preparation sessions
  10. Treatment sessions
  11. Appropriate behaviours
  12. Managing edge cases
  13. Key differences to standard therapy approaches
  14. Managing integration

Who is this workshop for?

This workshop is for any professional who wants to learn more about the rapidly emerging field of psychedelic medicine and the use of psychedelic-assisted therapies in clinical practice. This is a rare opportunity to learn from a global clinician and researcher in the field. It will provide you with knowledge and skills to more effectively educate your clients and colleagues about these newly available transformational therapies.

It is of even greater value for those who are interested in transitioning to work in the psychedelic medicine space now or in the future.

Tickets are strictly limited and early bird ticket offer ends on Friday October 27. Please register now before you miss out.


  • DATE: Friday 17 November 2023
  • TIME: 10:00am until 1:00pm workshop with catered lunch from 1:00pm-2:00pm
  • LOCATION: Sydney University, Susan Wakill Health Building, Seminar Room 322


Dr Ben Sessa (UK)

Psychiatrist, Researcher and Writer

For over 15 years Dr Ben Sessa has been at the forefront of psychedelic and cannabis research and clinical medicine in the UK through his affiliations with Imperial College London. Ben qualified as a medical doctor from UCL in 1997 and went on to specialise in psychiatry. For 25 years he has worked as a consultant child and adolescent psychiatrist with young people and adult patients in the field of addictions and trauma-related psychiatry.

Ben started studying psychedelics as a junior doctor and has taken part in research projects at Bristol University, Cardiff University and Imperial College London with LSD, psilocybin, DMT, ketamine and MDMA – receiving and/or administering all of these compounds in legal research settings.

One of the first doctors to develop the field of contemporary psychedelic research in the UK, he was the former co-founder, former CEO, and subsequently the former Head of Psychedelic Medicine at Awakn Life Sciences, a Bio-Tech company carrying out psychedelic research into addictions. Awakn opened four clinical centres in the U.K. and Europe, providing psychedelic psychotherapy with ketamine, for a wide range of psychiatric indications, as well as an extensive R&D psychedelic research program.

Ben was one of the first Medical Cannabis psychiatric prescribers in the UK.

Ben is a trained MDMA, ketamine and psilocybin therapist. He has led research into MDMA-assisted therapy for Alcohol Use Disorder and is published widely in the academic and medical press.

Ben is the co-founder and past president of the Breaking Convention conference. He is the author of The Psychedelic Renaissance (2012/2017), the novel ‘To Fathom Hell or Soar Angelic’ (2015) and Altered States (2021). Ben lives and works in Bristol, UK.



Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.


Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.


Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.

Powered by

The humane choice for tickets Humanitix donates 100% of profits from booking fees to children’s charities

Refund policy

No refund policy specified.